Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Invitae Corporation
The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.
Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- CombiMatrix Corporation
- Clear Genetics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.